Results 101 to 110 of about 13,103,023 (178)
Do we need more nucleos(t)ide analogs for the treatment of chronic hepatitis B?
Currently available antiviral treatment for chronic hepatitis B (CHB) infection can be divided into two classes of therapeutic agents: pegylated interferon alpha (PegIFN) and nucleos(t)ide analogues (NAs). The advantages of PegIFN include a finite course of treatment, the absence of drug resistance, and an opportunity to obtain a durable post-treatment
openaire +2 more sources
Background Chronic hepatitis B (CHB) is a major cause of hepatocellular carcinoma (HCC). In patients receiving CHB treatment, coexistence of steatotic liver disease (SLD) and cardiometabolic risk factors (CMRFs) markedly influence HCC risk.
Hung-Wei Wang +5 more
doaj +1 more source
Background and aims: Chronic hepatitis B infection is a global public health challenge, associated with significant morbidity and mortality. Nucleos(t)ide analogue treatment is crucial for disease management, but the optimal duration of treatment is ...
GOMES DIAS, J.
core
Nucleos(t)ides are essential for DNA/RNA synthesis, energy metabolism, and signaling, yet their roles in placental development remain poorly understood.
Antonin Libra +10 more
core +1 more source
Guichan Liao, Ziying Liu, Muye Xia, Hongjie Chen, Houji Wu, Bing Li, Tao Yu, Shaohang Cai, Xiaoyong Zhang, Jie Peng State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious ...
Liao G +9 more
doaj
Changes in renal function in CHB patients with Peg-IFN combined with nucleos(t)ide analogs
Abstract Background There is limited research comparing the renal safety of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) when used with pegylated interferon (pegIFN) in patients with chronic hepatitis B (CHB). Here, renal function changes in CHB patients were compared between treated with pegyIFN combined with ETV or TDF.
Jinhua Zhao +4 more
openaire +1 more source
Abstract Supplement HIV Glasgow 8–11 November 2026, Glasgow, UK/Virtual
Journal of the International AIDS Society, Volume 29, Issue S6, November 2026.
wiley +1 more source
Background Long-term therapy with nucleos(t)ide analogs (NUCs) is inevitable for chronic hepatitis B (CHB) patients. However, how NUC therapy on the developing Alzheimer’s disease (AD) in these patients remains controversial.
Jihye Lim +4 more
doaj +1 more source
Background: Liver dysfunction is common during coronavirus disease 2019 (COVID-19), while its clinical impact and association with chronic hepatitis B (CHB) remain uncertain.
Hao-Che Chang +6 more
doaj +1 more source
The aim of this systematic literature review (SLR) was to examine outcomes and associated predictors following nucleos(t)ide analog (NA) treatment cessation in adult patients with chronic hepatitis B virus infection.The SLR was conducted according to PRISMA methodology.
Robert Gish +8 more
openaire +3 more sources

